MedPath
HSA Approval

SIVEXTRO LYOPHILIZED POWDER FOR SOLUTION FOR INFUSION 200MG PER VIAL

SIN14851P

SIVEXTRO LYOPHILIZED POWDER FOR SOLUTION FOR INFUSION 200MG PER VIAL

SIVEXTRO LYOPHILIZED POWDER FOR SOLUTION FOR INFUSION 200MG PER VIAL

September 16, 2015

MSD PHARMA (SINGAPORE) PTE. LTD.

MSD PHARMA (SINGAPORE) PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantMSD PHARMA (SINGAPORE) PTE. LTD.
Licence HolderMSD PHARMA (SINGAPORE) PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

**2 DOSAGE AND ADMINISTRATION** **2.1 Recommended Dosage** The recommended dosage of SIVEXTRO is 200 mg administered once daily for six (6) days either orally (with or without food) or as an intravenous (IV) infusion in patients 18 years of age or older. The recommended dosage and administration is described in Table 1. ![Sivextro Dosage Table 1](https://cdn.medpath.com/drug/dosage/20240520/54ac58605c33ba2419d6ab141466f401.png) No dose adjustment is necessary when changing from intravenous to oral SIVEXTRO. If patients miss a dose, they should take it as soon as possible anytime up to 8 hours prior to their next scheduled dose. If less than 8 hours remain before the next dose, wait until their next scheduled dose. **2.2 Preparation and Administration of Intravenous Solution** SIVEXTRO is supplied as a sterile, lyophilized powder for injection in single-use vials of 200 mg. Each 200 mg vial must be reconstituted with Sterile Water for Injection and subsequently diluted only with 0.9% Sodium Chloride Injection, USP. SIVEXTRO vials contain no antimicrobial preservatives and are intended for single use only. Preparation The contents of the vial should be reconstituted using aseptic technique as follows: Note: To minimize foaming, AVOID vigorous agitation or shaking of the vial during or after reconstitution. 1. Reconstitute the SIVEXTRO vial with 4 mL of Sterile Water for Injection. 2. Gently swirl the contents and let the vial stand until the cake has completely dissolved and any foam disperses. 3. Inspect the vial to ensure the solution contains no particulate matter and no cake or powder remains attached to the sides of the vial. If necessary, invert the vial to dissolve any remaining powder and swirl gently to prevent foaming. The reconstituted solution is clear and colorless to pale-yellow in color; the total storage time should not exceed 24 hours at either room temperature (23°C – 25°C) or under refrigeration at 2°C to 8°C (36°F to 46°F). 4. Tilt the upright vial and insert a syringe with appropriately sized needle into the bottom corner of the vial and remove 4 mL of the reconstituted solution. Do not invert the vial during extraction. 5. The reconstituted solution must be further diluted in 250 mL of 0.9% Sodium Chloride Injection, USP. Slowly inject the 4 mL of reconstituted solution into a 250 mL bag of 0.9% Sodium Chloride Injection, USP. Invert the bag gently to mix. Do NOT shake the bag as this may cause foaming. Administration Administer as an intravenous infusion only. Do not administer as an intravenous push or bolus. Do not mix SIVEXTRO with other drugs when administering. It is not intended for intra-arterial, intramuscular, intrathecal, intraperitoneal, or subcutaneous administration. The intravenous bag containing the reconstituted and diluted intravenous solution should be inspected visually for particulate matter prior to administration. Discard if visible particles are observed. The resulting solution is clear and colorless to pale-yellow in color. After reconstitution and dilution, SIVEXTRO is to be administered via intravenous infusion using a total time of 1 hour. The total time from reconstitution to administration should not exceed 24 hours at room temperature (23°C – 25°C) or under refrigeration at 2°C to 8°C (36°F to 46°F). **2.3 Compatible Intravenous Solutions** SIVEXTRO is compatible with 0.9% Sodium Chloride Injection, USP. **2.4 Incompatibilities** SIVEXTRO for injection is incompatible with any solution containing divalent cations (e.g., Ca2+, Mg2+), including Lactated Ringer’s Injection and Hartmann’s Solution. Limited data are available on the compatibility of SIVEXTRO for injection with other intravenous substances, additives or other medications and they should not be added to SIVEXTRO single-use vials or infused simultaneously. If the same intravenous line is used for sequential infusion of several different drugs, the line should be flushed before and after infusion of SIVEXTRO with 0.9% Sodium Chloride Injection, USP.

INTRAVENOUS

Medical Information

**1 INDICATIONS AND USAGE** **1.1 Acute Bacterial Skin and Skin Structure Infections** SIVEXTRO is an oxazolidinone-class antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: _Staphylococcus aureus_ (including methicillin-resistant \[MRSA\] and methicillin-susceptible \[MSSA\] isolates), _Streptococcus pyogenes_, _Streptococcus agalactiae_, _Streptococcus anginosus_ Group (including _Streptococcus anginosus_, _Streptococcus intermedius_, and _Streptococcus constellatus_), and _Enterococcus faecalis_. **1.2 Usage** To reduce the development of drug-resistant bacteria and maintain the effectiveness of SIVEXTRO and other antibacterial drugs, SIVEXTRO should be used only to treat ABSSSI that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

**4 CONTRAINDICATIONS** SIVEXTRO is contraindicated in patients with known hypersensitivity to the active substance or to any of the excipients in the drug product.

J01XX11

tedizolid

Manufacturer Information

MSD PHARMA (SINGAPORE) PTE. LTD.

Patheon Italia S.p.A.

Active Ingredients

Tedizolid 165mg eqv Tedizolid phosphate

200mg

Tedizolid

Documents

Package Inserts

Sivextro_PI_Approved.pdf

Approved: July 27, 2022

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

SIVEXTRO LYOPHILIZED POWDER FOR SOLUTION FOR INFUSION 200MG PER VIAL - HSA Approval | MedPath